However, D1Rs are highly expressed in many tissues (Beaulieu and Gainetdinov, 2011) and broad use of D1R antagonists as a preventive treatment has important drawbacks including locomotor impairments (Giménez-Llort et al., 1997), or induce depression, parkinsonism and sedation in HD patients (Frank et al., 2008; Huntington Study Group, 2006). Here, DRD1 is linked to Huntington disease.